Amicus Therapeutics, Inc. (NASDAQ:FOLD) Chairman John F. Crowley Sells 6,044 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Chairman John F. Crowley sold 6,044 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $13.06, for a total transaction of $78,934.64. Following the completion of the transaction, the chairman now owns 914,009 shares in the company, valued at $11,936,957.54. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD traded down $0.21 on Monday, hitting $12.88. The company had a trading volume of 2,008,347 shares, compared to its average volume of 2,366,102. The company has a current ratio of 2.72, a quick ratio of 2.40 and a debt-to-equity ratio of 3.53. The company has a market cap of $3.70 billion, a PE ratio of -20.13 and a beta of 0.86. Amicus Therapeutics, Inc. has a 52-week low of $9.10 and a 52-week high of $14.10. The business has a 50 day moving average of $13.07 and a 200 day moving average of $12.25.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $89.57 million. Amicus Therapeutics had a negative return on equity of 157.79% and a negative net margin of 52.85%. As a group, equities analysts anticipate that Amicus Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.20.

Institutional Trading of Amicus Therapeutics

A number of institutional investors have recently modified their holdings of the company. Peregrine Capital Management LLC increased its position in shares of Amicus Therapeutics by 13.2% in the first quarter. Peregrine Capital Management LLC now owns 796,564 shares of the biopharmaceutical company’s stock worth $8,834,000 after acquiring an additional 92,697 shares in the last quarter. CIBC Private Wealth Group LLC lifted its stake in shares of Amicus Therapeutics by 9.7% during the fourth quarter. CIBC Private Wealth Group LLC now owns 22,705 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 2,005 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Amicus Therapeutics by 1.9% during the first quarter. Avoro Capital Advisors LLC now owns 27,300,000 shares of the biopharmaceutical company’s stock worth $302,757,000 after purchasing an additional 500,000 shares in the last quarter. Great Point Partners LLC purchased a new stake in shares of Amicus Therapeutics in the first quarter worth about $4,214,000. Finally, Macquarie Group Ltd. grew its stake in shares of Amicus Therapeutics by 3.1% in the first quarter. Macquarie Group Ltd. now owns 7,171,035 shares of the biopharmaceutical company’s stock valued at $79,527,000 after buying an additional 212,988 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.